$ALNY

AI 分析

生成於 May 11, 2026

AI Score
68/ 100
Hold$ALNY

Alnylam Pharmaceuticals

$ALNYNASDAQHealthcareLarge-Cap

Alnylam pioneers RNAi therapeutics for genetic diseases with Onpattro, Givlaari, and Oxlumo.

Market Cap
$32.0B
Revenue (TTM)
$2.5B
+45.0%
Net Income (TTM)
$0.1B
N/A
EPS (TTM)
$0.50
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$150-$270
Beta
0.72
Dimension Scores
Fundamental
60
Technical
64
Sentiment
74
Risk / Reward
58
Momentum
78
FundTechSentRiskMome
Financial Health
Profitability
65moderate
Growth
81strong
Liquidity
66strong
Solvency
62moderate
Efficiency
58moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $ALNY

Free · No credit card required

免責聲明: AI 生成的分析僅供教育參考,不構成投資建議。請始終諮詢合格的理財顧問。

探索更多

用 AI 分析任意股票

獲取涵蓋基本面、技術面、情緒面、風險評估和投資論點的結構化研究報告——約 60 秒完成。